1 completed. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Completed 1 |
Follow JAK2 Mutation: new trials by email Literature Review of JAK2 Mutation trials Research Report on JAK2 Mutation
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm Patients Apixaban 2.5 MG Oral Tablet [ELIQUIS], Aspirin 81 mg - Myeloproliferative Neoplasm (MPN), Essential Thrombocythemia (ET) | Phase 2 | Completed | Ottawa Hospital Research Institute | 44 | 2021-02-17 | 2024-05-29 |
Myeloproliferative Disorders (1) · Polycythemia Vera (1) · Primary Myelofibrosis (1) · Thrombocythemia, Essential (1) · Venous Thromboembolism (1)
Blood Coagulation Disorders (1) · Blood Platelet Disorders (1) · Bone Marrow Diseases (1) · Bone Marrow Neoplasms (1) · Cardiovascular Diseases (1) · Embolism and Thrombosis (1) · Hematologic Diseases (1) · Hematologic Neoplasms (1) · Hemic and Lymphatic Diseases (1) · Hemorrhagic Disorders (1) · Neoplasms (1) · Neoplasms by Site (1) · Thrombocytosis (1) · Thromboembolism (1) · Vascular Diseases (1)
Aspirin (1) · Tablets (1) · apixaban (1)
Ottawa Hospital Research Institute (1)
Canada (1)
Aurelien Delluc, MD, PhD (1) · Miriam Kimpton, MD (1)